Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

Pulido et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69def5c692a5e9426ae93efe — DOI: https://doi.org/10.1056/nejmoa1213917

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinical worsening in trials of pulmonary arterial hypertension: results and implications· 2010 · 39 citations
2. Tadalafil Therapy for Pulmonary Arterial Hypertension· 2009 · 1,089 citations
3. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension· 2008 · 1,078 citations
4. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist· 2008 · 325 citations
5. Validation Of Six-Minute-Walk Distance As A Surrogate Endpoint In Pulmonary Arterial Hypertension Trials· 2012 · 4 citations